Floatz logo

PROPOFOL

Middle Cerebral Artery Stroke

Johns Hopkins UniversitySmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Middle Cerebral Artery Stroke cohort.

Asset / SponsorPhaseRating
ARUNDIC ACID
Merck Sharp & Dohme LLC
Phase 2CCC
Human Placenta-Derived Cells Pda001-
Celularity Incorporated
Phase 2CCC
TEONANACATL
Johns Hopkins University
Phase 1CC
Fycompa
National Cheng Kung University
N/AD
Keppra
National Cheng Kung University
N/AD

Same molecule, other indications

PROPOFOL is also rated in:

Pain, ChronicDormant
BBB
Indicative ·
79 / 100
View asset →
headache disorderDormant
BBB
Indicative ·
73 / 100
View asset →
morbid obesityDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →